RAD50 and cancer: In contrast to the hMre11 and Rad51 data, the fraction of Rad50 foci-positive cells (Figure 5C, filled symbols) in the irradiated cells from hypersensitive cancer patients (88%) was significantly higher (<0.005) than in control cells (41%) and cells from cancer patients with normal reaction to RT (44%).